Gossamer Bio (GOSS) vs Mereo BioPharma Group (MREO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Mereo BioPharma Group (MREO) has outperformed Gossamer Bio (GOSS) over the past year, losing 80.9% versus a loss of 94.9%. Over five years, MREO leads with a -82.8% price change compared with -99.1% for GOSS. Gossamer Bio is the larger company by market cap ($58.5 million vs $57.6 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GOSS | MREO |
|---|---|---|
| Share price | $9.56 | $0.3608 |
| Market cap | $58.47M | $57.62M |
| 1-day change | -3.24% | -3.84% |
| YTD return | -96.02% | -10.02% |
| 1-year return | -94.90% | -80.86% |
| 5-year return | -99.12% | -82.79% |
| EPS (TTM) | $-52.80 | $-0.20 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $309.60 | $2.37 |
| 52-week low | $9.12 | $0.20 |
| Distance from 52-week high | -96.91% | -84.78% |
| Analyst consensus | buy | none |
| Avg. price target upside | +762.76% | +443.24% |
| Average volume | 378.37K | 4.04M |
| Shares outstanding | 6.12M | 159.69M |
| Employees | 161 | 39 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MREO has outperformed GOSS by 14.0 percentage points over the past year.
About Gossamer Bio
GOSS stock →Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.
Health Care · Biotechnology: Pharmaceutical Preparations · 161 employees
About Mereo BioPharma Group
MREO stock →Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of rare diseases in the United Kingdom and the United States. The company develops Setrusumab, an antibody for the treatment of osteogenesis imperfecta; Alvelestat, an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency associated lung disease; and Vantictumab, an anti-FZD monoclonal antibody for the treatment of autosomal dominant osteopetrosis type 2.
Health Care · Biotechnology: Pharmaceutical Preparations · 39 employees
GOSS vs MREO FAQ
Which is bigger, Gossamer Bio or Mereo BioPharma Group?
Gossamer Bio (GOSS) is larger, with a market capitalization of $58.47M compared with $57.62M for Mereo BioPharma Group (MREO).
Which stock has performed better over the past year, GOSS or MREO?
MREO returned -80.86% over the past 12 months, compared with -94.90% for GOSS (price return, excluding dividends). Past performance does not predict future results.
Are Gossamer Bio and Mereo BioPharma Group in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.